Smmttx.com

Promising Intracranial Anti-Tumor Activity and Safety Data for

WebAbout Ivonescimab Ivonescimab, known as SMT112 in Summit’s license territories, the United States, Canada, Europe, and Japan, and as AK112 in China and …

Actived: 3 days ago

URL: https://www.smmttx.com/pressrelease/promising-intracranial-anti-tumor-activity-and-safety-data-for-ivonescimab-in-nsclc-patients-with-brain-metastases-featured-at-elcc-2024/

Intracranial Anti-Tumor Activity and Safety of Ivonescimab in …

Web2 About the ELCC 2024 Posters Poster Title: Phase 2 Results of Ivonescimab a Novel PD-1/VEGF Bispecific in Combination with Chemotherapy for First Line Treatment of …

Category: Health Go Health

Promising Intracranial Anti-Tumor Activity and Safety Data for

Web3 About Ivonescimab Ivonescimab, known as SMT112 in Summit’s license territories, the United States, Canada, Europe, and Japan, and as AK112 in China and Australia, is an …

Category: Health Go Health

Summit Therapeutics Closes Deal with Akeso Inc. to In-License

WebSummit Therapeutics’ Mission Statement To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial …

Category: Health Go Health

H. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, …

WebSummit Therapeutics’ Mission Statement To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial …

Category: Health Go Health

Summit Therapeutics Announces First Patient Treated in …

WebIvonescimab, known as SMT112 in the United States, Canada, Europe, and Japan(Summit’s license territories), and as AK112 in China and Australia, is a novel, potential first-in …

Category: Health Go Health

Ivonescimab’s Novel Mechanism of Action Highlighting …

Web2 Earlier this year, the first patient was treated in Summit’s license territories in the Phase III HARMONi clinical trial. Summit has opened clinical trial sites in the HARMONi-3 trial and …

Category: Health Go Health

Summit Therapeutics to Present at the Barclays 26th Annual …

Web1 Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference Miami, Florida, March 05, 2024 – Summit Therapeutics Inc. (NASDAQ: …

Category: Health Go Health

Summit Therapeutics Announces Updated Phase II Data

Web4 have EGFR-sensitizing mutations in the United States and Europe.5 Patients with squamous histology represent approximately 25% to 30% of NSCLC patients. 6 About …

Category: Health Go Health

Summit Therapeutics Announces First Patient Treated in

WebSummit Therapeutics’ Mission Statement To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial …

Category: Health Go Health

Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins …

Web3 evaluation of the underlying data in connection with the development and commercialization activities for SMT112, the outcome of discussions with regulatory …

Category: Health Go Health

Summit Therapeutics Closes Fully-Subscribed $500 Million Rights

WebMenlo Park, California, March 3, 2023 – Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced the successful closing of …

Category: Health Go Health

Summit Therapeutics to Present at the 42nd Annual J.P. Morgan

WebMenlo Park, California, January 3, 2024 – Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will …

Category: Health Go Health

Summit Therapeutics Announces Updated Phase II Data

WebMiami, FL, January 08, 2024 – Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced substantial updates to the promising …

Category: Health Go Health

Business Development

WebBusiness Development Partnering Opportunities Summit Therapeutics is actively seeking business development opportunities to make a significant difference for the betterment of …

Category: Health Go Health